Add Glucokinase Activator to Target A1c

Exclusion Criteria

• •Diagnosis of Type 1 diabetes mellitus, maturity-onset diabetes of the young, insulin-requiring Type 2 Diabetes, other unusual or rare forms of diabetes mellitus, or history of diabetic ketoacidosis.
• •Clinically significant abnormal lab values including eGFR \<50ml/min/1.73m2, ALT, bilirubin or AST \>1.5 X ULN, hypokalemia or other clinically significant electrolyte abnormality.
• •History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack within 2 years of screening.
• •Presence of symptomatic congestive heart failure.
• •History of cardiac arrhythmias requiring treatment or prophylaxis with drugs or devices during the last 2 years or any history of atrial fibrillation or flutter beyond a single short-term episode (e.g., lasting 1-2 days).
• •History or presence of a 2nd degree or greater atrioventricular block in the absence of a pacemaker.
• •A 12-lead ECG, from screening or baseline demonstrating QTcF interval \>450 msec for males or \>47 msec for females.
• •A family or personal history of long QT syndrome.
• •History of pancreatitis.
• •Persistent, uncontrolled hypertension.
• •Presence of chronic active hepatitis (hepatitis B, hepatitis C, nonalcoholic steatohepatitis \[NASH\]) and/or known liver cirrhosis.
• •Participation in any formal weight loss program, or fluctuation of \> 5% in body weight, or having received medications approved for weight loss within 3 months prior to screening.
• •A positive pre-study drug screen.
• •Participation in a clinical trial and receipt of an investigational product within 30 days.
• •Have a history of drug abuse within 2 years of screening or a positive pre-screen drug screen.
• •Have a history of hypoglycemic episode requiring glucose, glucagon, or orange juice administered by someone other than the patient within 6 months prior to screening.
• •A history of excessive alcohol consumption within the last 2 years prior to screening
• •Mental or legal incapacitation.
• •Blood donation of approximately 1 pint (500 mL) within 8 weeks.
• •History of MEN-2 or family history of medullary thyroid cancer.
• •History of cancer, other than non-melanoma skin cancer, that required therapy in the 5 years prior study start.